Natixis Advisors LLC Makes New $288,000 Investment in Dynavax Technologies Co. (NASDAQ:DVAX)

Natixis Advisors LLC purchased a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 22,536 shares of the biopharmaceutical company’s stock, valued at approximately $288,000.

A number of other hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 2,034 shares during the period. GAMMA Investing LLC lifted its stake in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Dynavax Technologies during the 4th quarter valued at about $71,000. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares in the last quarter. Finally, KBC Group NV increased its stake in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 2,857 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Shares of DVAX opened at $13.68 on Friday. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 76.00 and a beta of 1.23. The firm’s fifty day simple moving average is $13.35 and its 200-day simple moving average is $12.49. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Equities analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on DVAX. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.